Human Immunodeficiency Virus Type 1 (HIV 1) Market

Human Immunodeficiency Virus Type 1 (HIV 1) Market Size, Market Forecast and Outlook By FMI

The human immunodeficiency virus type 1 (hiv 1) market was valued at USD 39.10 billion in 2025, projected to reach USD 41.45 billion in 2026, and is forecast to expand to USD 74.22 billion by 2036 at a 6.0% CAGR. Expanding antiretroviral therapy access, evolving treatment guidelines favoring integrase inhibitor-based regimens, and global scale-up of test-and-treat programs are sustaining consistent demand growth across both established and emerging therapeutic markets.

Summary of Human Immunodeficiency Virus Type 1 (HIV 1) Market

• The market is on track to reach USD 74.22 billion by 2036.
• Growth is pegged at a 6.0% CAGR over the 2026 to 2036 forecast window.
• As of 2025, the market was valued at USD 39.10 billion.
• Cumulative incremental value across the forecast stands at USD 32.78 billion.
• Integrase Inhibitors leads by Drug Class with 35.7% share in 2026.
• Demand is sustained by global treatment scale-up programs targeting the UNAIDS 95-95-95 goals across both high-prevalence and concentrated epidemic settings.
• Among key countries, China leads at 8.1% CAGR, followed by India at 7.5%, Germany at 6.9%, France at 6.3%, UK at 5.7%.

Human Immunodeficiency Virus Type 1 (HIV 1) Market Key Takeaways

Metric	Details
Industry Size (2026)	USD 41.45 billion
Industry Value (2036)	USD 74.22 billion
CAGR (2026-2036)	6.0%

Source: Future Market Insights, 2026

Treatment paradigm consolidation around single-tablet regimen formulations continues to reshape competitive dynamics across the HIV therapeutics market. FMI analysts note that integrase strand transfer inhibitor-based combinations have displaced protease inhibitor backbones as first-line standard of care in most national treatment guidelines. Generic competition in older drug classes is compressing revenue in mature markets while long-acting injectable formulations create new premium pricing tiers that partially offset volume-driven price erosion.

Country-level growth projections reflect treatment coverage gaps, generic penetration timelines, and regulatory pathway differences. China at 8.1%, India at 7.5%, Germany at 6.9%, France at 6.3%, UK at 5.7%, USA at 5.1%, Brazil at 4.5%. China leads expansion driven by central government commitment to achieve UNAIDS 95-95-95 targets through accelerated treatment initiation and domestic generic production scaling. India maintains strong growth through national program procurement of affordable integrase inhibitor-based regimens and expanded testing infrastructure. Germany and France sustain growth through early adoption of long-acting injectable regimens and comprehensive insurance coverage. The United Kingdom and United States reflect mature markets with growth driven by treatment innovation uptake and adherence program optimization. Brazil expands through public health system procurement and domestic manufacturing capacity development.

Human Immunodeficiency Virus Type 1 (HIV 1) Market Definition

The Human Immunodeficiency Virus Type 1 (HIV-1) Market encompasses prescription antiretroviral therapeutics used in the treatment and clinical management of HIV-1 infection. Drug classes include integrase strand transfer inhibitors, nucleoside and nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry and fusion inhibitors, and coreceptor antagonists. Products span originator branded formulations, generic equivalents, single-tablet regimens, fixed-dose combinations, and long-acting injectable preparations prescribed across first-line, second-line, and salvage therapy settings.

Human Immunodeficiency Virus Type 1 (HIV 1) Market Inclusions

Market scope includes prescription antiretroviral drug revenue across all approved drug classes for HIV-1 treatment, encompassing originator and generic formulations, single-tablet and multi-tablet regimens, and long-acting injectable products. Revenue from first-line, second-line, and salvage therapy prescriptions across all regional markets is included.

Human Immunodeficiency Virus Type 1 (HIV 1) Market Exclusions

The scope excludes HIV-2 specific therapeutic products, pre-exposure prophylaxis formulations, HIV diagnostic testing platforms and assay revenue, antiretroviral manufacturing equipment, and clinical trial expenditure for investigational compounds not yet approved for commercial distribution.

Human Immunodeficiency Virus Type 1 (HIV 1) Market Research Methodology

• Primary Research: Analysts conducted structured interviews with national treatment program directors, hospital formulary committee members, antiretroviral procurement specialists, and infectious disease physicians to map prescribing pattern evolution and formulary decision dynamics.
• Desk Research: Data collection phases aggregated UNAIDS treatment cascade reports, national antiretroviral treatment guideline publications, pharmaceutical company annual reports, WHO prequalification databases, and published clinical trial outcome data.
• Market-Sizing and Forecasting: Baseline values derive from a bottom-up aggregation of product-level and service-level revenue data, applying region-specific adoption curves and regulatory timeline assumptions to project future demand trajectories through the forecast period.
• Data Validation and Update Cycle: Projections are cross-validated against publicly reported revenue guidance from leading industry participants, government procurement disclosures, and published epidemiological or market data from recognized multilateral organizations.

Key Drivers Supporting Growth in the HIV 1 Treatment Market

Burgeoning HIV/AIDS Incidence to Push Market Growth

One of the key contributing factors expected to propel market growth is the rising prevalence of HIV/AIDS, particularly in Africa. According to the World Health Organization (WHO), an estimated 36.9.0 million people were living with HIV infection in 2024, with 1.5 million [1.1 million-2.0 million] new HIV infections.

According to WHO, women and girls constituted 54% of all HIV-positive people. This large patient population in various regions is driving up demand for antiretroviral (ARV) drugs. Furthermore, the government is working to improve HIV-1 patients' access to treatment and assessment. This is expected to fuel the global HIV-1 market.

Combined efforts of the government and several NGOs to propel the market growth

The deliberate initiatives of the government and multiple NGOs to supply at-risk individuals with better exposure to disease diagnosis and treatment for infected patients are key factors driving the HIV-1 market growth.

Numerous companies, including Cipla, Inc. and Gilead Sciences, Inc., have also implemented diagnosis education programs to lessen the detrimental ramifications of infectious diseases. The potential growth of this market is heavily reliant on the unfulfilled assessment and treatment needs in African and Asian countries.

Challenges Projected to Restrain Expansion in the HIV 1 Therapeutics Sector

Scarcity of Treatment Access and Lack of awareness of HIV Infection Status May Stifle Growth

Despite advances in technology development, enhanced scientific knowledge of HIV, and the affordability of therapeutic approaches, some detaining aspects are reducing future growth. Many individuals who are HIV-positive or at risk of becoming HIV-positive are unable to get timely treatment access. Besides that, there is no treatment for this virus.

As reported by the Joint United Nations Program on HIV/AIDS (UNAIDS), for instance, diagnosis metrics are distributed unevenly around the world. The lack of sufficient treatment options continues to be a challenge in middle-income and emerging nations, stifling the expansion of the HIV1 market.

Analysis of Regional Trends Influencing HIV 1 Diagnosis and Care

What Makes North America the Largest Market for Human Immunodeficiency Virus Type 1 (HIV 1)?

North America's dominance is due to the high prevalence of HIV infection

With a market share of USD 39.1 Billion in 2026, North America dominated the market. This region's dominance is credited to the rising incidence of HIV infection in the US citizenry. Based on a study performed by the Centers for Disease Control (CDC) in 2039.1, an estimated 29.2 million people were living with HIV at the end of 2020.

With such a large patient population, the requirement for HIV drugs skyrockets. The population's consciousness is another aspect that contributes to regional growth. Furthermore, the presence of prominent players providing new HIV medications for the treatment of HIV1 transmission would augment the market growth.

Why is Asia Pacific Considered a Lucrative Region for the Human Immunodeficiency Virus Type 1 (HIV 1) Market?

Because of its dense population, the Asia Pacific market is the fastest-growing region

Owing to the highly populous nations, like China and India, with a huge proportion of HIV patients, the Asia Pacific market is predicted to be the fastest-growing market with the largest CAGR over the forecast period. Moreover, the vast number of therapeutic interventions and financial support from the private sector and medical companies are expected to propel the industry.

For example, Gilead Sciences, Inc., one of the world's biggest antiretroviral drug manufacturers, declared a USD 36.9 Million funding for its 'Gilead Asia Pacific Rainbow Grant Program' in Asia Pacific in December 2024. The program consists of Gilead's initiative to strengthen public-private collaborations in the Asia Pacific region in order to tackle the difficulties posed by HIV-infected patients.

HIV 1 Industry Analysis by Top Investment Segments

Which Type Leads the Market for Human Immunodeficiency Virus Type 1 (HIV 1)?

Integrase inhibitors are preferred as first-line treatments for recently diagnosed patients

As the primary line of treatment for HIV, the integrase inhibitors segment held the second-highest market share in 2026, supporting the growth of the segment. Integrase inhibitors are advised as initial treatments for newly diagnosed HIV infection by the International AIDS Society (IAS).

The non-nucleoside reverse transcriptase inhibitors (NRTIs) segment has the smallest share of the market due to significantly fewer requirements for this drug class compared to the late innovative pharmaceutical launches

Emerging Start-ups Driving Innovation in the HIV 1 Treatment Landscape

• Y Combinator is a technology start-up activator in the USA that was founded in March 2005. The Immunity Project is creating a free HIV/AIDS vaccine using a novel approach involving data analysis and machine learning. It is one of seven charitable organizations in the current batch of the elite accelerator program Y Combinator.
• Argu Soft India Limited is a start-up company that was founded on August 21, 2000. It is headquartered in Gandhi Nagar, Gujarat, India. ArguSoft developed a health app to inhibit AIDS transmission from mother to child and is collaborating with the Indian government and charitable groups to combat the disease efficaciously.

Leading Companies in the HIV 1 Market Competitive Environment

Key players in the Human Immunodeficiency Virus Type 1 (HIV 1) market are AbbVie, Inc, Boehringer, and Ingelheim GmbH. Bristol-Myers Squibb Company, Cipla, Inc, Genentech, Inc, Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline, Sanofi.

• In July 2024 - Unitaid and the Clinton Health Access Initiative, Inc. (CHAI) declared a pricing contract with the medical company Hetero Labs LTD to create darunavir combined with ritonavir (DRV/r) obtainable as a second-line treatment for HIV patients in low and moderate-income nations for USD 210 per patient/year.
• Gilead Sciences Inc. and Merck revealed a partnership deal in March 2024 to co-develop and co-commercialize lengthy HIV treatment. Gilead's investigational capsid inhibitor lenacapavir and Merck's investigational nucleoside reverse transcriptase translocation inhibitor islatravir will be combined to produce a two-drug regimen for HIV.
• In January 2024 - HIV Cabenuva, an injectable drug approved by the US Food and Drug Administration for the treatment of human immunodeficiency virus type 1 (HIV) infections in adults, was developed by ViiV Healthcare.

Scope of the Report

Metric	Value
Quantitative Units	USD 41.45 billion to USD 74.22 billion, at a CAGR of 6.0%
Market Definition	The Human Immunodeficiency Virus Type 1 (HIV-1) Market encompasses prescription antiretroviral therapeutics used in the treatment and clinical management of HIV-1 infection. Drug classes include integrase strand transfer inhibitors, nucleoside and nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry and fusion inhibitors, and coreceptor antagonists. Products span originator branded formulations, generic equivalents, single-tablet regimens, fixed-dose combinations, and long-acting injectable preparations prescribed across first-line, second-line, and salvage therapy settings.
Segmentation	Drug Class: Integrase Inhibitors, Nucleoside-Analog Reverse Transcriptase Inhibitor, Non-Nucleoside Reverse Transcriptase Inhibitor, Entry and Fusion Inhibitors, Protease Inhibitors, Coreceptor Antagonists
Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East & Africa
Countries Covered	China, India, Germany, France, UK, USA, Brazil, and 40 plus countries
Key Companies Profiled	Gilead Sciences, Inc., AbbVie, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla, Inc., Genentech, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline, Sanofi
Forecast Period	2026 to 2036
Approach	Forecasting models apply a bottom-up methodology starting with product-level revenue metrics and cross-validate projections against enterprise spending guidance and regulatory adoption timelines.

Top Segments Profiled in the HIV 1 Market Industry Survey

By Drug Class:

• Nucleoside-Analog Reverse Transcriptase Inhibitor
• Non-Nucleoside Reverse Transcriptase Inhibitor
• Entry and Fusion Inhibitors
• Protease Inhibitors
• Integrase Inhibitors
• Coreceptor Antagonists

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)

Bibliography

• 1. UNAIDS. (2024). Global AIDS Update 2024: The Urgency of Now. UNAIDS.
• 2. World Health Organization. (2024). Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring. WHO.
• 3. U.S. Department of Health and Human Services. (2024). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. HHS.
• 4. Gilead Sciences, Inc. (2024). Annual Report 2024. Gilead investor relations filing.
• 5. The Global Fund. (2024). Results Report 2024. The Global Fund to Fight AIDS, Tuberculosis and Malaria.
• 6. European Medicines Agency. (2024). Human Medicines Highlights 2024. EMA.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with primary research documentation.